Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

v3.23.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:    
NET LOSS $ (117,319) $ (1,029,225)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 65,041 65,287
Equity-based compensation 4,259 17,211
Goodwill impairment 0 851,456
Amortization of original issue discount and debt issuance costs 405 0
Accretion of contingent consideration 113 291
Mark-to-market adjustment of stock warrants 327 (3,386)
Premium deficiency reserve (9,361) (10,116)
Changes in assets and liabilities:    
Health plan receivable (45,258) (31,247)
Clinic fees, insurance, and other receivable 5,275 (1,623)
Prepaid expenses and other current assets (429) 3,462
Other long-term assets (1,214) 0
Accounts payable, accrued expenses, and other current liabilities 2,758 4,560
Accrued payroll 2,405 1,054
Health plan settlements payable 21,814 (1,922)
Claims payable 4,290 32,747
Accrued interest 7,092 3,885
Operating lease liability (348) 3,501
Net cash used in operating activities (60,150) (94,065)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of property and equipment (2,039) (2,283)
Acquisitions, net of cash acquired 0 (5,500)
Net cash used in investing activities (2,039) (7,783)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from long-term debt, net of original issuance discount 14,101 0
Proceeds from private placement offering, net of offering costs paid 87,244 0
Repayment of short-term and long-term debt 0 (3,625)
Payment of debt issuance costs (173) 0
Net cash provided by (used in) financing activities 101,172 (3,625)
Net change in cash and restricted cash 38,983 (105,473)
Cash and restricted cash, beginning of period 18,457 140,834
Cash and restricted cash, end of period $ 57,440 $ 35,361